These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Erythropoietin and myocardial protection: what's new? Joyeux-Faure M; Godin-Ribuot D; Ribuot C Fundam Clin Pharmacol; 2005 Aug; 19(4):439-46. PubMed ID: 16011730 [TBL] [Abstract][Full Text] [Related]
3. [An experimental study of recombinant human erythropoietin on the treatment of acute myocardial infarction in rats]. Ye L; Du XL; Xia JH; Jiang P; Wang JT; Fan HM; Liu ZM Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(39):2776-80. PubMed ID: 17199998 [TBL] [Abstract][Full Text] [Related]
4. Is there a role for erythropoietin in cardiovascular disease? Vogiatzi G; Briasoulis A; Tousoulis D; Papageorgiou N; Stefanadis C Expert Opin Biol Ther; 2010 Feb; 10(2):251-64. PubMed ID: 20028188 [TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin (rHuEPO): more than just the correction of uremic anemia. Buemi M; Aloisi C; Cavallaro E; Corica F; Floccari F; Grasso G; Lasco A; Pettinato G; Ruello A; Sturiale A; Frisina N J Nephrol; 2002; 15(2):97-103. PubMed ID: 12018644 [TBL] [Abstract][Full Text] [Related]
6. Erythropoietin and neuroprotection: a therapeutic perspective. Milano M; Collomp R J Oncol Pharm Pract; 2005 Dec; 11(4):145-9. PubMed ID: 16595066 [TBL] [Abstract][Full Text] [Related]
7. Erythropoietin and treatment of non-anemic conditions--cardiovascular protection. Fliser D; Haller H Semin Hematol; 2007 Jul; 44(3):212-7. PubMed ID: 17631185 [TBL] [Abstract][Full Text] [Related]
8. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Li Y; Takemura G; Okada H; Miyata S; Maruyama R; Li L; Higuchi M; Minatoguchi S; Fujiwara T; Fujiwara H Cardiovasc Res; 2006 Sep; 71(4):684-94. PubMed ID: 16828072 [TBL] [Abstract][Full Text] [Related]
9. Cellular protection by erythropoietin: new therapeutic implications? Joyeux-Faure M J Pharmacol Exp Ther; 2007 Dec; 323(3):759-62. PubMed ID: 17717190 [TBL] [Abstract][Full Text] [Related]
10. Experimental models of acute renal failure and erythropoietin: what evidence of a direct effect? Sturiale A; Campo S; Crascì E; Aloisi C; Buemi M Ren Fail; 2007; 29(3):379-86. PubMed ID: 17497457 [TBL] [Abstract][Full Text] [Related]
11. Constitutively overexpressed erythropoietin reduces infarct size in a mouse model of permanent coronary artery ligation. Camici GG; Stallmach T; Hermann M; Hassink R; Doevendans P; Grenacher B; Hirschy A; Vogel J; Lüscher TF; Ruschitzka F; Gassmann M Methods Enzymol; 2007; 435():147-55. PubMed ID: 17998053 [TBL] [Abstract][Full Text] [Related]
13. Erythropoietin in cancer: the new face of an old friend. Megalakaki C J BUON; 2008; 13(1):7-16. PubMed ID: 18404780 [TBL] [Abstract][Full Text] [Related]
14. Erythropoietin and its non-erythropoietic derivative: do they ameliorate renal tubulointerstitial injury in ureteral obstruction? Srisawat N; Manotham K; Eiam-Ong S; Katavetin P; Praditpornsilpa K; Eiam-Ong S Int J Urol; 2008 Oct; 15(11):1011-7. PubMed ID: 18759748 [TBL] [Abstract][Full Text] [Related]
15. [Erythropoietin: indications and measurement]. Klein E; Georges A; Brossaud J; Bosredon Kd; Bordenave L; Corcuff JB Ann Biol Clin (Paris); 2009; 67(5):505-15. PubMed ID: 19789122 [TBL] [Abstract][Full Text] [Related]
16. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. Brines M; Cerami A J Intern Med; 2008 Nov; 264(5):405-32. PubMed ID: 19017170 [TBL] [Abstract][Full Text] [Related]
17. Control of erythropoietin gene expression and its use in medicine. Jelkmann W Methods Enzymol; 2007; 435():179-97. PubMed ID: 17998055 [TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition. Ehrenreich H; Bartels C; Sargin D; Stawicki S; Krampe H J Ren Nutr; 2008 Jan; 18(1):146-53. PubMed ID: 18089462 [TBL] [Abstract][Full Text] [Related]